» Articles » PMID: 12223114

Impact of HIV Vaccination on Laboratory Diagnosis: Case Reports

Abstract

Background: It has not been clearly demonstrated whether HIV vaccination can complicate routine HIV testing. In this report, we describe the laboratory data of two prisoners who received rgp120 vaccine in a phase III trial underway in Thailand. These data indicate that previous vaccination may complicate the interpretation of screening HIV diagnostic tests.

Case Presentation: The participants were identified from a cohort study on "Health factors related to HIV-1 and other viral infections among incarcerated people" that was approved by The Ethical Committee for Research in Human Subjects, Ministry of Public Health, Thailand. HIV diagnosis was definitively established with serial specimens using multi-screening tests, Western blot and diagnostic PCR.Anti-HIV screening tests consistently exhibited either weakly reactive or inconclusive results. The band patterns of the Western blot analysis corresponded to those found in individuals who received the rgp120 vaccination. Definite results were established using diagnostic PCR, which exhibited consistently negative results with follow-up specimens. Such problems in HIV testing are not easily resolved in the routine clinical setting in Thailand.

Conclusions: These data demonstrate that HIV-1 vaccination interferes with routine diagnostic tests. Similar cases will not be uncommon in Thailand, where 2,545 people have already participated in a phase III trial.

Citing Articles

Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.

Penezina O, Krueger N, Rodriguez-Chavez I, Busch M, Hural J, Kim J Clin Vaccine Immunol. 2014; 21(3):391-8.

PMID: 24403525 PMC: 3957658. DOI: 10.1128/CVI.00748-13.

References
1.
Migasena S, Suntharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C, Huang W . AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retroviruses. 2000; 16(7):655-63. DOI: 10.1089/088922200308882. View

2.
Allen M, Israel H, Rybczyk K, Pugliese M, Loughran K, Wagner L . Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses. 2001; 17(8):667-74. DOI: 10.1089/088922201750236942. View

3.
BERMAN P, Gray A, Wrin T, Vennari J, Eastman D, NAKAMURA G . Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 1997; 176(2):384-97. DOI: 10.1086/514055. View

4.
Francis D, Gregory T, McElrath M, Belshe R, Gorse G, Migasena S . Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses. 1998; 14 Suppl 3:S325-31. View

5.
Phanuphak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S . International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol. 1997; 15(1):41-8. View